Serum prostate specific antigen as a predictor of survival in prostate cancer patients treated with second-line hormonal therapy (CALGB 9181)

Prostate Journal

Volumn 3, Issue 1, 2001, Pages 18-25

  Halabi, Susan ^a,f   Conaway, Mark R ^b   Small, Eric J ^c   Vogelzang, Nicholas J ^d   Dawson, Nancy A ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; MEGESTROL ACETATE; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

EID: 0034857461     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2001.31003.x     Document Type: Article

References (29)

1. Prostate-specific antigen and history of its discovery
2. Apples and oranges: Building a consensus for standardized eligibility criteria and endpoints in prostate cancer clinical trials
3. Using the serum prostate-specific antigen (PSA) to screen and manage prostate cancer
4. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer
5. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
6. Serum markers as predictors of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate
7. Casodex versus castration in treatment of stage D2 prostate cancer: Prostate specific antigen (PSA) as a measure of outcome
8. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
9. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
10. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
11. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
12. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
13. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of Cancer and Leukemia Group B 9182 study
14. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
15. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
16. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: Cancer and Leukemia Group B (CALGB) study 9181
17. Analysis of survival by tumor response
18. Flutamide in hormone-resistant prostatic cancer
19. Suramin induced decrease in PSA is associated with prolonged objective progression-free (OPFS) and overall survival in hormone-refractory prostate cancer (HRPC)
20. Results of CALGB 9480, a phase III trial of 3 different doses of Suramin for the treatment of hormone refractory prostate cancer (HRPC)
21. The dynamics of PSA in hormone-refractory prostate cancer: An analysis of CALGB 9181 of megestrol acetate
22. A prognostic score for hormone-refractory prostate cancer: Analysis of two Cancer and Leukemia Group B studies
23. Prostate specific antigen doubling time in the diagnosis and follow-up of patients with prostate cancer
24. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
25. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment
26. Hormone and antihormone withdrawal: I. Implications for the management of androgen-independent prostate cancer
27. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
28. The antiandrogen withdrawal syndrome
29. Eligibility and response guidelines for clinical trials in androgen independent prostate cancer: Recommendations from the PSA Working Group